85 randomized 2690 patients undergoing
lower extremity bypass to coumarin (target international
normalized ratio of 3-4.5) vs ASA (81 mg/d). Overall, there
was no difference in patency at 12 months in the two cohorts;
however, a subgroup analysis demonstrated superior patency
for patients undergoing vein bypass receiving coumarin
compared with those receiving ASA alone at 12 and 24 months
(OR